drugset / Trial / NCT02302989
Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration
Phase 1/2
Completed
4 enrolled
Leonard Feiner, MD, PhD
NJ Retina (Retina Associates of New Jersey) · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
To evaluate Ranibizumab as prophylaxis against the conversion to neovascular Age-Related Macular Degeneration
Timeline
- Start
- 2015-05
- Primary completion
- 2018-07
- Completion
- 2018-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |